Retatrutide Overcomes Treatment Resistance in Obese Triple-Negative Breast Cancer
Pharmacological Dissection Identifies Retatrutide Overcomes the Therapeutic Barrier of Obese TNBC Treatments through Suppressing the Interplay between Glycosylation and Ubiquitylation of YAP.
Background
Triple-negative breast cancer (TNBC) is an exceptionally aggressive and challenging subtype of breast cancer, characterized by the absence of common therapeutic targets, making it particularly difficult to treat effectively. A significant and growing concern is the strong link between obesity and TNBC, where obesity not only increases the risk of developing TNBC but also worsens its prognosis and frequently leads to treatment resistance. This critical study was designed to meticulously investigate the precise molecular mechanisms by which obesity exacerbates TNBC treatment resistance and to explore novel pharmacological interventions, specifically Retatrutide, that could potentially overcome this significant therapeutic barrier.